IL3RA过表达急性髓系白血病的基因组与转录组特征:预后及治疗意义再探讨
本研究首先证实IL3RA mRNA与CD123蛋白水平强相关,并在国际共识分类(ICC)框架下刻画了IL3RA在各分子亚组中的表达模式,发现FUS::ERG、CBFB::MYH11、高危KMT2A融合、NPM1突变和DEK::NUP214的AML中IL3RA过表达。IL3RA过表达患者总生存和无事件生存显著更差,且可外部验证;IL3RA高表达AML对维奈克拉和sapanisertib显示选择性敏感。
要点
- IL3RA mRNA与CD123蛋白水平强相关,可在ICC框架下区分AML分子亚组。
- FUS::ERG、CBFB::MYH11、高危KMT2A融合、NPM1突变和DEK::NUP214的AML中IL3RA过表达。
- IL3RA过表达患者总生存和无事件生存显著更差,且可外部验证。
核心结论
- IL3RA过表达定义了临床和生物学上独特的AML亚组,具有独特的治疗脆弱性;需继续研究将CD123靶向治疗整合入AML一线治疗范式。
研究设计与样本
- 研究首先验证IL3RA mRNA与CD123蛋白水平的相关性,并在国际共识分类(ICC)框架下分析IL3RA在不同分子定义亚组中的表达模式。
主要发现
- IL3RA在FUS::ERG、CBFB::MYH11、高危KMT2A融合、NPM1突变和DEK::NUP214的AML中过表达。
- IL3RA过表达患者的总生存和无事件生存显著更差,且可外部验证。
- IL3RA高表达AML以HOX家族基因上调以及白血病干细胞和IL-3信号转录程序为生物学特征。
- 药物转录组分析显示IL3RA高表达AML对维奈克拉和sapanisertib显示选择性敏感,提示潜在协同机会。
临床怎么用
- 作者认为IL3RA过表达定义了具有独特治疗脆弱性的AML亚组,需继续研究将CD123靶向治疗整合入AML一线治疗范式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD123 (encoded by IL3RA) is intricately linked to the maintenance of haematopoietic progenitors. In acute myeloid leukaemia (AML), as CD123 is overexpressed on the leukaemic stem cells (LSC), several CD123-directed therapies are currently undergoing active clinical evaluation. However, a major gap remains in understanding which AML genetic subgroups would benefit most from interventions targeting CD123 in the context of the contemporary International Consensus Classification (ICC). Therefore, in this study, we first demonstrated the strong correlation between IL3RA mRNA and CD123 protein levels and then characterized IL3RA expression patterns across various molecularly defined subgroups within the ICC framework. We discovered that IL3RA was particularly overexpressed in AML with FUS::ERG, CBFB::MYH11, high-risk KMT2A fusions, NPM1 mutations and DEK::NUP214. Patients with IL3RA overexpression exhibited significantly worse overall and event-free survivals, which could be externally validated. Biologically, IL3RA-high AML was characterized by upregulated HOX family genes as well as LSC and IL-3 signalling transcriptional programmes. Pharmaco-transcriptomic analysis revealed that IL3RA-high AML exhibited selective sensitivity to venetoclax and sapanisertib, suggesting potential synergistic opportunities. In conclusion, IL3RA overexpression defines a clinically and biologically distinct subgroup of AML, with unique therapeutic vulnerabilities. Continued research efforts are warranted to integrate CD123-directed therapies into the upfront AML treatment paradigm.
引用
- Yao CY, Hsu CL, Yang YT, et al. Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited. Br J Haematol. 2025. PMID: 41250875. doi:10.1111/bjh.70252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。